PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsZanubrutinib
Brukinsa(zanubrutinib)
Brukinsa (zanubrutinib) is a small molecule pharmaceutical. Zanubrutinib was first approved as Brukinsa on 2019-11-14. It is used to treat mantle-cell lymphoma in the USA. It has been approved in Europe to treat waldenstrom macroglobulinemia. It is known to target tyrosine-protein kinase BTK.
Download report
Favorite
FDA Novel Drug Approvals 2019
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Brukinsa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zanubrutinib
Tradename
Company
Number
Date
Products
BRUKINSABeigeneN-213217 RX2019-11-14
1 products, RLD, RS
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mantle-cell lymphoma—D020522C83.1
Agency Specific
FDA
EMA
Expiration
Code
ZANUBRUTINIB, BRUKINSA, BEIGENE
2030-01-19ODE-274
2028-09-14ODE-370
2028-08-31ODE-371
2026-11-14ODE-276
2026-01-19I-817
2024-11-14NCE
2024-09-14I-874
2024-08-31I-871
Patent Expiration
Patent
Expires
Flag
FDA Information
Zanubrutinib, Brukinsa, Beigene
117865312043-01-19U-3715, U-3716, U-3717, U-3718, U-3719, U-3720
119113862043-01-19U-3715, U-3716, U-3717, U-3718, U-3719, U-3720
109271172037-08-15DS, DP
115913402037-08-15U-1745 , U-2145 , U-2537, U-2666 , U-3063 , U-3486
118514372037-08-15DS, DP
118846742037-08-15U-1745, U-2145, U-2537, U-2666, U-3063, U-3486
94471062034-04-22DS, DPU-1745, U-2145, U-2537, U-2666, U-3063, U-3486
105701392034-04-22U-1745, U-2145, U-2537, U-2666, U-3063, U-3486
111425282034-04-22DPU-1745, U-2145, U-2537, U-2666, U-3063, U-3486
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EL: Bruton's tyrosine kinase (btk) inhibitors
— L01EL03: Zanubrutinib
HCPCS
No data
Clinical
Clinical Trials
124 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403—C83.34152——19
B-cell chronic lymphocytic leukemiaD015451—C91.14123——16
Mantle-cell lymphomaD020522—C83.1582——12
Waldenstrom macroglobulinemiaD008258HP_0005508C88.0261—310
Non-hodgkin lymphomaD008228—C85.9111——3
Hodgkin diseaseD006689—C81——1——1
Membranous glomerulonephritisD015433EFO_0004254N03.2—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD016393——33——15
Follicular lymphomaD008224—C8233——15
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3—4———4
NeoplasmsD009369—C8012———2
LymphomaD008223—C85.911———2
TherapeuticsD013812———2———2
Lymphoid leukemiaD007945—C91—1———1
Lupus nephritisD008181EFO_0005761——1———1
Immunoglobulin g4-related diseaseD000077733—D89.84—1———1
Covid-19D000086382—U07.1—1———1
Show 7 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———7————7
Myelodysplastic syndromesD009190—D461————1
Myeloid leukemia acuteD015470—C92.01————1
B-cell lymphoma marginal zoneD018442—C88.41————1
Hepatic insufficiencyD048550——1————1
LeukemiaD007938—C951————1
T-cell lymphomaD016399——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0————22
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameZanubrutinib
INNzanubrutinib
Description
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
Identifiers
PDB—
CAS-ID1651179-04-2
RxCUI—
ChEMBL IDCHEMBL3936761
ChEBI ID—
PubChem CID135565884
DrugBankDB15035
UNII IDAG9MHG098Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
BTK
BTK
Organism
Homo sapiens
Gene name
BTK
Gene synonyms
AGMX1, ATK, BPK
NCBI Gene ID
695
Protein name
tyrosine-protein kinase BTK
Protein synonyms
agammaglobulinaemia tyrosine kinase, Agammaglobulinemia tyrosine kinase, ATK, B-cell progenitor kinase, BPK, Bruton agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, Bruton's tyrosine kinase, dominant-negative kinase-deficient Brutons tyrosine kinase
Uniprot ID
Q32ML5
Mouse ortholog
Btk (12229)
tyrosine-protein kinase BTK (Q61365)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,224 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
242 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use